Company / Capital Expenditures
LENZ Therapeutics, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$827.0K
FY2025
5-year range
$30.0K / $6.6M
FY2021-FY2025
Trend
+76.7%
vs FY2024
Sector context
#120 of 194
Health Care
What the data says
At $827,000, LENZ Therapeutics, Inc.'s capital expenditures ranks #120 of 194 in the Health Care sector. Improved from $30,000 to $827,000 over the past 2 years.
Based on SEC 10-K filings.
$827,000 in FY2025 with a 5-year CAGR of -11.7%.
Improved from $30,000 to $827,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -49.9%
- 5-Year CAGR
- -11.7%
- 10-Year CAGR
- -
Sector benchmark
#120 of 194 in Health CareTop 62% of 194This company $827.0K Sector average $117.5M
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.7%, indicating a declining trend.
- In FY2025, capital expenditures increased 76.7% year-over-year.
- Ranks #120 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $827.0K | +76.7% |
| FY2024 | $468.0K | +1460.0% |
| FY2023 | $30.0K | -99.5% |
| FY2022 | $6.6M | +14.9% |
| FY2021 | $5.7M | +271.5% |
| FY2020 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026